Aldeyra Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALDX research report →
Companywww.aldeyra.com
Aldeyra Therapeutics, Inc. , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.
- CEO
- Todd C. Brady
- IPO
- 2014
- Employees
- 9
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $91.08M
- P/E
- -3.33
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 1919339.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.00%
- ROIC
- -0.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-33,846,661 · 39.40%
- EPS
- $-0.56 · 40.43%
- Op Income
- $-35,265,206
- FCF YoY
- -77173352.87%
Performance & Tape
- 52W High
- $6.17
- 52W Low
- $1.07
- 50D MA
- $1.98
- 200D MA
- $4.37
- Beta
- 1.15
- Avg Volume
- 3.14M
Get TickerSpark's AI analysis on ALDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 27, 26 | Brady Todd C | other | 1,880,510 |
| Mar 27, 26 | Brady Todd C | other | 632,318 |
| Mar 19, 26 | DOUGLAS RICHARD | buy | 70,000 |
| Mar 18, 26 | Alfieri Michael | buy | 5,000 |
| Aug 13, 25 | Alfieri Michael | buy | 2,500 |
| Aug 11, 25 | Machatha Stephen | sell | 22,073 |
| Jun 10, 25 | Walker Neal | other | 62,728 |
| Jun 10, 25 | Walker Neal | other | 2,413 |
| Jun 10, 25 | Miller-Rich Nancy | other | 62,728 |
| Jun 10, 25 | Miller-Rich Nancy | other | 2,413 |
Our ALDX Coverage
We haven't published any research on ALDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALDX Report →